Albiges L et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 2020;5(6):e001079. Abstract
Attalla K et al. Prevalence and landscape of actionable genomic alterations in renal cell carcinoma. ASCO Genitourinary Cancers Symposium 2020;Abstract 616.
Bauer TM et al. The oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): Updated follow-up of a phase I/II study. ASCO Genitourinary Cancers Symposium 2021;Abstract 273.
Choueiri TK et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2021;384(9):829-41. Abstract
Choueiri TK et al. Phase 2 study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC). ASCO Genitourinary Cancers Symposium 2021;Abstract 272.
Ged Y et al. DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy. J Immunother Cancer 2020;8(1):e000230. Abstract
Lee C-H et al. Genomic biomarkers of response to lenvatinib/pembrolizumab (len/pembro) in patients with advanced renal cell carcinoma. ASCO Genitourinary Cancers Symposium 2020;Abstract 733.
Motzer RJ et al. Nivolumab + cabozantinib (NIVO + CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER. ASCO Genitourinary Cancers Symposium 2021;Abstract 308.
Motzer RJ et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2021;384(9):829-41. Abstract
Pal S et al. Cabozantinib (c) in combination with atezolizumab (a) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from the COSMIC-021 study. ESMO 2020;Abstract 702O.
Pal SK et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: A randomised, open-label, phase 2 trial. Lancet 2021;397:695-703. Abstract
Powles T et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): Extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol 2020;21(12):1563-73. Abstract
Rini BI et al. Tivozanib in patients with advanced renal cell carcinoma (aRCC) who have progressed after prior treatment of axitinib: Results from TIVO-3. ASCO Genitourinary Cancers Symposium 2021;Abstract 278.
Taylor MH et al. Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J Clin Oncol 2020;38(11):1154-63. Abstract
Teo MY et al. Clinicogenomic predictors of extreme responses to anti-PD1/PDL1 checkpoint inhibitors (CPI) in metastatic urothelial cancer (mUC). ASCO 2020;Abstract 5050.